VIFOR-PHARMA
2.2.2021 07:02:08 CET | Business Wire | Press release
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Alexandre LeBeaut was formerly Chief Scientific Officer and Executive Vice-President R&D at Ipsen Bioscience Inc. with more than 25 years of extensive global R&D experience in the biopharmaceutical industry including Schering-Plough, Novartis, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. Alexandre is a French and US citizen and a pediatrician who holds a M.D. from Paris University. He is a member of the Board of Calypso Biotech.
After 25 years with Vifor Pharma and four years of service on the Board of Directors, Dr Gianni Zampieri has decided that he will not stand for re-election to the Board at the Annual General Meeting in 2021. “With his expertise and valuable insights, Gianni Zampieri has been instrumental in the strategic development of the company in various roles. Because of his profound strategic foresight he drove the development and the launch of Ferinject, which is now a blockbuster product for the company.” As CEO for Vifor Pharma he successfully managed the separation of the group and the IPO of Galenica. Gilbert Achermann has also decided to step down from the Board of Vifor Pharma and therefore does not stand for re-election. “On behalf of the Board of Directors, I extend our sincere gratitude to both Directors for their excellent and successful work for Vifor Pharma, and we wish them all the best for their private and professional future” said Jacques Theurillat.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005792/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom